scholarly journals The Appropriateness of Fresh Frozen Plasma (FFP) Administration in the Community Teaching Hospital

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 5823-5823
Author(s):  
Sufana Shikdar ◽  
Nicholas Ghionni ◽  
Eric Green ◽  
Kakageldi Hommadov

Abstract Objective: Studies demonstrated that inappropriate usage of fresh frozen plasma (FFP) is associated with adverse reaction and poor health outcome in the hospitalized patients. Reducing inappropriate FFP administration in the inpatient settings can minimize potential for adverse events, and foster controllable cost expenditure. Guideline regarding indication of FFP transfusion is scarce. We aimed to assess the appropriateness of FFP transfusion in the setting of community teaching hospital. Methods: A retrospective chart review of patients received FFP transfusion in two community teaching hospitals between 2016-2017 were included in our study. Frequency of appropriateness of FFP transfusion was reported. We also reported percent increase from previous years to compare the FFP usage from 2010-2011 to 2016-2017. Results: Of 138 patients received FFP transfusion in 2016-2017, 62% (86 patients) received inappropriate transfusion. 18% of patients received FFP to correct high INR (>1.6) requiring emergency surgery. 53% of the patients received inappropriate transfusion for bleeding in 2016-2017 compared to 25% in 2010-2011. There was 10% rise of inappropriate or overuse of FFP transfusion in 2016-2017 than 2010-2011. Conclusion: Inappropriate FFP transfusion is significantly associated with adverse health outcome and increased healthcare cost. This study justifies the need for continuous audit for appropriate use of FFP. Disclosures No relevant conflicts of interest to declare.

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 5789-5789 ◽  
Author(s):  
Sufana Shikdar ◽  
Kavita Agrawal ◽  
Nicholas Ghionni ◽  
Kakageldi Hommadov ◽  
Shahrzad Abdollahi ◽  
...  

Objective: Although Fresh Frozen Plasma (FFP) is indicated in critically ill patients, there are growing concerns about it's cost effectiveness and adverse effects in instances that do not conform to evidence-based indications. Despite a range of adverse reaction with the inappropriate usage of FFP, its usage has significantly increased over the last decade. We previously evaluated the overuse of FFP in our community teaching hospital in 2010-2011 and 2016-2017. The interventions to reduce the inappropriate FFP transfusion were implemented after the results from 2016-2017. The present multicenter study is a post-interventional study that describes practices regarding administration of FFP in three community teaching hospitals between 2017-2018. Methods: A retrospective chart review of patients who received FFP transfusion in three community teaching hospitals between 2017-2018 were included in our study. Criteria were established to evaluate the appropriateness of FFP. Descriptive statistics were utilized to compare the appropriateness of FFP transfusion among the participating hospitals. Results: Overall, 306 participants were evaluated where 25% of the participants (77 out of 306) received inappropriate FFP transfusions. The most common rationale for inappropriate FFP transfusions were bleeding with INR less than 1.5 followed by INR over 1.5 (without any evidence of active bleeding).Based on our study criteria, the proportion of inappropriate FFP transfused out of the total FFP transfused decreased from 49% in the study period 2016-2017 to 25% in the study period 2017-2018. 15% of the study population received inappropriate FFP transfusion for bleeding in 2017-2018 compared to 42% in 2016-2017. Conclusion: Our study showed a reduction in inappropriate FFP transfusions in 2017-2018 compared to 2016-2017. This can be attributed to the interventions implemented after obtaining study results from 2016-2017. The interventions included creating fliers educating about lack of effectiveness of FFP to reduce INR below 1.6 and arranging educational talks from transfusion committee about the evidence-based usage of FFP transfusion. Such interventions are essential to reduce healthcare expenditure and transfusion related adverse events. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 5278-5278
Author(s):  
Luis Fernando Cortázar-Benítez ◽  
Pablo Vargas Viveros ◽  
Alfredo Aiza Alvarez ◽  
Rafael Hurtado Monroy

Abstract Abstract 5278 HIA due to ozone exposure on patients with glucose 6 phosphate dehydrogenase deficiency (G6PDd) is extremely rare. The purpose of this report is to describe in detail a case of HIA and DVT on a woman without G6PDd, with a successful treatment with fresh frozen plasma (FFP) transfusion and Thrombolysis. The patient is a 36 years old woman, that 3 months before she was diagnosed with multiple sclerosis (MS) because paresthesias in the fingers of her left foot and she received treatment with blood ozone exposure (at unknown dose) in 3 sessions each week for 3 months. The patient attended to our center with severe anemic syndrome during the last 2 weeks and disabling pain of her left leg of 12 hours of evolution. Physical examination showed pale ++++, jaundice ++, functional systolic murmur grade IV, without adenomegaly or splenomegaly, increasing volume, induration, erythema and intense pain from the ankle to the popliteal space of her left leg. The urine was dark. Laboratory data were haemoglobin 5 g/dL, hematocrit 17%, reticulocytes 62%, and platelets 281×109/L. Peripheral blood smear showed esquistocytes +++ and spherocytes ++, suggesting intravascular hemolysis. Total bilirrubin 2.99mg/dL, direct bilirubin 0.57, and LDH 750 U/L. Doppler ultrasound: obstruction of the deep and superficial venous system of tibial, peroneal and left popliteal veins. Four red cells units were transfused and FFP transfusion was started every 6 hours, anticoagulation with enoxaparina sodium (1mg/Kg/day) and thrombolysis with rhTPA 100 mg for 3 hours infusion. The patient successfully improved with increase and maintenance of hemoglobin, decrease of the reticulocytes count and evident clinical improvement of her left leg. She was in-hospital for 8 days at the end of which was achieved ambulation, Doppler showed remission of DVT. The association between exposure to ozone and HIA has not been informed in the absence of G6PD deficiency, and today, little is known of the ideal treatment. Though plasmapheresis is the treatment of choice in a HIA, the presence of DVT and be in a period appropriate for thrombolysis, determined the use of FFP transfusion as the main treatment. The right clinical evolution observed in the treatment of our patient gave her solving clinical problems. Ozone has been widely used for a variety of off-label purposes. In vitro experiments had demonstrated hemolysis with ozone concentration > 30 mcg/mL, therefore this case must represent an important alert for those ozone users, however the mechanism of hemolysis because ozone exposure remains to be elucidated. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 4375-4375
Author(s):  
Raghava Reddy Levaka Veera ◽  
Doron Schneider ◽  
Peter V. Pickens

Abstract Abstract 4375 BACKGROUND: The use of Fresh Frozen Plasma (FFP) has increased considerably in recent years. In the USA there was 70% increase in the use of plasma in 10 years between 1991 and 2001. Around 3.9 million units were transfused in 2001 and 5.7 million units in 2009. FFP is often used inappropriately globally and studies evaluating FFP use in the US are scarce. We conducted a study to assess the trends of FFP use, its implications, appropriateness, and impact of FFP on International Normalized Ratio (INR) in hospitalized adult medical patients with an elevated INR. DESIGN AND METHODS: The study was a retrospective audit of all adult medical in-patients with an INR of 1.2 or higher who received FFP during a 3 month period from December 1, 2011 to February 28, 2012 admitted to Abington Memorial Hospital. A list of all patients who received FFP during the study period was obtained from the blood bank. Patients with major trauma, surgical, post-op, pediatric and obstetric/gynecological patients were excluded. Data was collected on demographics, indications of FFP, pre and post transfusion INR and effect of FFP on pre-transfusion INR. Partial thromboplastin time values (PTT) were not collected. RESULTS: A total of 479 units of FFP were transfused to 97 patients over 114 transfusion episodes. Of the 97 patients, 51 were male (52.6%) and 46 were female (47.3%) with a mean age of 70.4 yrs (median 73 yrs, range 19–95 yrs). Of the total 479 units of FFP, 233 units (48.6%) were given to patients who were not actively bleeding (n=53) with a mean pre-transfusion INR (pre-INR) of 2.82 (range 1.5 to >10, SD 1.6). Warfarin related coagulopathy was noted in 65 patients (67%) and 340 units of FFP (71%) were transfused to these patients. FFP units transfused as pre-procedural prophylaxis were 176 out of 479 (36.7%). Twenty transfusion episodes amounting to 53 units of FFP (11.1%) were given to patients who were not actively bleeding and had a pre-INR of <2. Six patients did not get the planned procedure done and received 25 units (5.2%) of FFP. Of 15 patients who received FFP as pre-procedure prophylaxis with INR <2, only one (6.6%) had normalized post-transfusion INR (post-INR), 5 (33.3%) had post-INR of <1.5 and none had any bleeding complications. Inappropriate use of FFP in this study was noted to be 23.7% (114/479 units of FFP). Mean improvement in INR per unit of FFP for all transfusion episodes (n=114) was 0.36, with mean pre-INR of 3.28 (range 1.5 to >10) and mean post-INR of 1.72 (range 1.2 to 4.2). Mean improvement in INR/FFP in patients with pre-INR <2 vs. those with pre-INR 2 or higher was 0.22 vs. 0.42 respectively (p=0.021). Mean improvement in INR/FFP was significantly higher in patients with warfarin related coagulopathy vs. in those secondary to other causes (0.46 vs. 0.33, p=0.001). Patients who received vitamin K concurrently with FFP had higher mean improvement in INR/FFP than those who did not receive vitamin K (0.45 vs. 0.17, p=0.001). It was also noted that timing of post-INR check was very heterogeneous. Two patients developed an allergic reaction needing stoppage of transfusion and further treatment. Approximately $6,840 were wasted in direct costs ($60 per unit) in just 3 months for only medical in-patients excluding indirect costs (estimated at $100 per unit= $11,400) such as technician, nursing time; transfusion sets, pre-medication, etc. CONCLUSION: Inappropriate use of FFP remains high even among medical in-patients. This study is consistent with previous studies in finding warfarin reversal as the major indication of FFP use and higher the pre-INR, higher was the improvement in INR. Especially, high percentage of use of FFP for pre-procedural prophylaxis with mild elevation of INR is alarming; therefore, studies evaluating restrictive vs. liberal use of FFP are needed. *ICU=Intensive care unit, PCU= Progressive care unit, ER= Emergency room, GMF= General medical floor. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 4981-4981
Author(s):  
Ian Garrahy ◽  
Tushar Pawar ◽  
Anthony Donato ◽  
Amber Stevenson ◽  
Daniel Forman

Introduction: The bleeding risk of warfarin is well known. Therapeutic options for warfarin reversal in life-threatening bleeds include fresh frozen plasma (FFP), recombinant factor VIIa (rFVIIa), and prothrombin complex concentrate (PCC). Despite the theoretical advantage and clinical evidence supporting PCC, it is not widely used in the US. Methods: An online anonymous questionnaire was sent to all providers in the Tower Health System asking them about their practice, specialty, degree, years in practice, and basic questions regarding their comfort and frequency of prescribing anticoagulants. The questionnaire also asked the providers how they would manage ten various clinical scenarios related to anticoagulation management. One question specifically addressed the management of warfarin reversal in an 85-year-old presenting with hemorrhagic shock. Analysis of variance was used to compare the scoring means between groups while linear regression and Pearson's correlation coefficient measured the relationship between years of practice and test scores. Results: Out of 404 responders, 232 (57.4%) selected an incorrect answer and 212 (52.5%) incorrectly selected fresh frozen plasma as the answer to the question (see uploaded image) that addressed warfarin reversal in the setting of major bleeding. Those providers who answered this question correctly and those who answered it incorrectly had mean scores of 68.26% and 52.16% respectively on the overall survey (p value 0.000). Conclusion: As compared to FFP, the use of PCC for warfarin reversal is associated with a significant reduction in all-cause mortality. This project demonstrates a professional practice gap and serves to highlight an area in medicine where many providers are not practicing in accordance with evidence-based practice. Furthermore, this particular question from the survey discovered that providers who performed better on the survey were more likely to answer questions regarding anticoagulation reversal correctly. Figure Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 2341-2341
Author(s):  
Charles S Greenberg ◽  
Caroline Dupre Vaughn ◽  
Joseph Meserve ◽  
Adrian Reuben ◽  
Ming Yeong Lim ◽  
...  

Abstract Fresh frozen plasma is often prescribed for correction of the INR prior to invasive procedures in patients with cirrhosis. The coagulopathy associated with cirrhosis is attributed to abnormalities in platelets, fibrinogen levels and coagulation factor levels. There are conflicting opinions regarding the need to correct any abnormality prior to invasive procedures. The purpose of this study was to develop a ROTEM-based algorithm to support hemostasis in patients with cirrhosis having an invasive procedure. ROTEM represents an FDA approved instrument that provides a series of assays to monitor the initiation, propagation and stabilization of fibrin. We conducted preliminary studies using ROTEM assays in cirrhosis and found that the ROTEM assays are sensitive to changes in platelet count( < 80K), clotting factor levels (<30%) and fibrinogen levels (< 150mg%), making it a suitable assay to guide factor replacement in cirrhosis. To validate the utility of ROTEM assays, we incorporated ROTEM testing into our standard work-up of coagulopathy in liver disease. We performed routine PT, aPTT, fibrinogen, clotting factor levels (Factors V and VII) and hematocrit in parallel to ROTEM assays. We initially studied 50 stable patients from hepatology clinic with cirrhosis that had a median meld score of 16, PT INR of 1.8 and platelet count of 77K. We found that 25% of patients had normal ROTEM assays despite an abnormal set of screening coagulation assays. Furthermore, the time to initiate a clot (CT) was sensitive to low factor levels. The EXTEM was more sensitive than the INTEM CT (10% abnormal vs 5%). The INTEM clot formation time (CFT) was more sensitive to platelet count than the EXTEM CFT and became abnormal with platelets <85K. This prelimnary study validated the sensitivity and speficicty of the ROTEM assays in cirrhosis. The CFT represents an early time point in forming a fibrin gel and correlates with the rapid formation of thrombin. Fibrin must form rapidly to be effective. This led us to utilize a single clinician to guide the transfusion management of cases with cirrhosis prior to invasive procedures using The ROTEM algorithm. 44 pts with cirrhosis were treated ; they had 99 procedures performed (47 High-Moderate risk: biopsy, TIPS) and 52 low risk procedures (paracentesis, PICC line). The average INR was 2.2. No patient was denied treatment, nor was any attempt made to rely solely on the ROTEM assay to decide on plasma, cryo or platelet transfusion. Prolongation of CT > 5 sec normal range was used to infuse 2 units FFP; prolongation of CFT was used to infuse platelets and FIBTEM less than 9 was used to infuse cryo. 41U of FFP were transfused (0.4 U FFP per case), 16 Units cryo and 16 units of platelets (0.16 transfusion per case). The previous institutional use based on correcting INR for 99 cases was 297 U FFP, realizing a cost savings of 86%. No bleeding or other adverse events related to the transfusions were reported. When a second clinician reviewed blood product selection based on ROTEM values alone, there was agreement regarding use of FFP, cryo and platelets in 84% of the transfusion orders. ROTEM testing alone could be used to manage these cases without correcting the INR and is the subject of future studies.. The ROTEM assay became available for use by the hepatology and ICU services and no hematology consult was required for testing. This allowed clinical services to use ROTEM assays as part of their patient management in cirrhosis. We audited the use of ROTEM and did not detect any widely consistent use of ROTEM parameters to guide treatment. The average use of FFP in these cases was 5-fold higher than our protocol. In conclusion, we have developed a ROTEM-based algorithm for managing the coagulopathy of cirrhotic patients prior to invasive procedures. This ROTEM guided approach reduces the use of FFP and avoids complications caused by attempts to use FFP to the INR, which is not always feasible and potentially dangerous. Fututre studies are planned to address the optimum ROTEM assays and specific assay values for recommending use of FFP. cryo and platelets. Disclosures No relevant conflicts of interest to declare.


2020 ◽  
Author(s):  
Cyril PERNOD ◽  
Laurie Fraticelli ◽  
Guillaume Marcotte ◽  
Bernard Floccard ◽  
Thibaut Girardot ◽  
...  

Abstract Background: Uncontrolled haemorrhage is still the leading cause of preventable death following trauma. Coagulation resuscitation strategies can be plasma-based or fibrinogen concentrate-based. The aim of this study was to describe the evolution of transfusion practices following the introduction of tranexamic acid (TXA) and ROTEM® in a trauma centre from a teaching hospital.Methods: This is a single-centre, retrospective study at a Trauma Resuscitation Unit (TRU) from a French teaching hospital. All trauma patients aged 18 years or more and transfused with at least 4 red blood cells (RBCs) within 24 hours after trauma, from 2011 to 2016, were included. The primary objective was to analyse transfusion practices over this time period.Assessment of the annual proportion of patients transfused with more than 4 RBCs at 24h, proportion of application of high fresh frozen plasma (FFP):RBC ratio (≥ 1:2 ), and proportion of administration of fibrinogen with ROTEM® protocol and TXA was performed. The secondary objectives aimed at assessing differences between populations according to the FFP:RBC ratio applied and compare all-cause mortality at D30.Results: A total of 122 patients were included. Between 2011 and 2016, there was a significant decrease in the proportion of patients requiring at least 4 RBCs 24h after trauma (9% vs. 3%, Ptrend < 0.0001) as well as a decrease in the proportion of patients with a high FFP:RBC ratio (86% vs. 62% at 6h, Ptrend = 0.0056 and 86% vs. 56% at 24h, Ptrend = 0.0047). After 2013, fibrinogen was administered to more than 70% of patients and TXA to 100% of them. Adherence to the ROTEM® protocol for the administration of fibrinogen was significant. The observed mortality was lower than the predicted one, irrespective of FFP:RBC ratio.Conclusion: From 2011 to 2016, an important evolution of practices occurred in the TRU including a decrease in the proportion of transfusions and use of high FFP:RBC ratios. The origin of these changes is multifactorial, likely including the systematic use of TXA and optimisation of the ROTEM® protocol for fibrinogen administration.


Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 1464-1464 ◽  
Author(s):  
Amanda Bruder Rassi ◽  
Tania RFR Rocha ◽  
Alberto Q Farias ◽  
Livia Caroline Barbosa Mariano ◽  
Elbio Antonio D'Amico

Abstract Introduction: In vitro studies have shown that transfusion of fresh frozen plasma (FFP) has limited efficacy in correcting coagulopathy in cirrhosis. This study aims to assess the effect of FFP transfusion on endogenous thrombin potential (ETP) in patients with cirrhosis with abnormal coagulation test results. Methods: Using a stringent protocol for control of pre-analytic variables, blood samples were collected before and up to 8 hours after FFP transfusion. All samples were tested for INR, aPTT and ETP. The ETP assay was performed in platelet-poor plasma, using an automated fluorometer (CAT, Netherlands), using the technique developed by Hemker and modified by Tripodi. ETP was defined as the area under ROC curve and results were expressed as the ratio of ETP with thrombomodulin addition to ETP without (used to mimic in vivo conditions when patients are transfused). Results: 42 patients were included (male n=28; Child-B n= 11; Child-C n=31). Patients underwent FFP transfusion prior to high-risk invasive procedures (n=25), for treatment of bleeding (n=10) or for both reasons (n=6). The mean dose of FFP was 11.3 ml/kg (95% CI 9.16 - 20.46). After transfusion, INR decreased from 2.6±1,4 to 2.09±0.5 (p<0.0001) and aPTT from 1.47±0.5 to 1.27±0.26 (p<0.0001). At baseline, normal or above normal values of ETP ratio (³0.66) were found in 37 (88%) patients, and mean values remained largely unchanged after FFP transfusion (0.75±0.22; median 0.82 before to 0.76±0.16; median 0.81 after transfusion; p=0.56). The results for INR, aPTT and ETP are shown in figure 1. During the one-week follow-up period, 4 patients (9,5%) had acute reactions to transfusion, including fluid overload and allergic reactions. Of the 31 patients that underwent invasive procedures, four had severe bleeding. Discussion: FFP transfusion at standard doses ameliorated INR and aPTT, but did not increase thrombin generation corrected by thrombomodulin. That might be explained by the fact the former tests detect only 5% of the amount of thrombin generated. Besides, they are performed without the addition of thrombomodulin, an endothelial protein with anticoagulant effects, to which patients with cirrhosis have shown to be resistant. Patients were exposed to the risks of transfusions, without a clear benefit in the improvement in thrombin generation and decreasing the risk of bleeding. Our results call into question the common use of INR and aPTT for guiding the transfusion policy of FFP when treating coagulopathy in cirrhosis. Figure 1: Results showing comparison before and after FFP transfusion for (A) INR, (B) aPTT and (C) ETP ratio with and without thrombomodulin. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 1126-1126
Author(s):  
Alex Politsmakher ◽  
Dipanita Barua ◽  
Harvey Dosik

Abstract Abstract 1126 Background: The complications of blood transfusions and the increased morbidity and mortality associated with liberal use of blood products have been convincingly demonstrated. The clinical problems they pose have prompted development of evidence-based transfusion guidelines. Nevertheless, most hospitals do not enforce these guidelines and effective strategies have not been developed. Continuing medical education, such as conferences, do not appear to be effective in changing physician behavior, as confirmed in the literature and by our hospital's experience. New York Methodist Hospital therefore undertook a more proactive approach to reduce unnecessary transfusions and in the process to change physicians' attitude toward transfusions. Methods: In October 2008, our hospital implemented strict criteria for transfusions of all blood products including red blood cells (RBC), platelets, fresh frozen plasma, and cryoprecipitate. These criteria were applied by selected experienced clinicians who each served as monitors for their own clinical department. The blood bank required the approval of the monitor to release blood products that did not meet the criteria. This helped ensure that patients who indeed require transfusion based on clinical situation would be treated appropriately. Physicians had easy access to the monitors 24 hours a day, 365 days a year. Transfusion requests from operating rooms and post-anesthesia care units were excluded from monitoring. Transfusion of patients with active bleeding was also exempted because it was included in the RBC justification criteria. In most patients with symptomatic anemia, a single unit of RBC was approved. We compared data from the 12 months preceding (Year 1) and the 12 months after the enforcement of the criteria (Year 2). The data included the number of hospital admissions, the amount of blood products transfused per month, the type and number of transfusion-related complications, and the number of type and screens performed by the blood bank. Results: Transfusion usage declined sharply from Year 1 to Year 2: RBC use fell by 27.9% (9,149 vs. 6,599 units), fresh frozen plasma use fell by 40.3 % (3,615 vs. 2,158), platelets use fell by 22.1 % (1,207 vs. 940), and cryoprecipitate use fell by 37.4% (1,421 vs. 890). These decreases occurred in the face of a 2.9% increase in hospital admissions over 12 months (from 35,348 to 36,421). The decreased transfusion use was accompanied by reduced complications, which declined by 28.6 % (35 transfusion reactions in Year 1 vs. 25 in Year 2). The total cost of blood products declined by $1,027,869 (from $3,694,069 in Year 1 to $2,666,200 in Year 2). The number of type and screen tests requested and performed in the hospital also decreased by 6.3% (from 28,488 in Year 1 to 26,681 in Year 2). Conclusion: We report our one-year experience with a new model for improving transfusion use. Monitoring and intervention in described settings with possibilities of appeal reduced transfusion use by 22–40%. It also appeared to modify physician attitude as exemplified by a 6.3% reduction in type and screen requests in spite of 2.9% increase in admissions. Although small, this decline supports the trend toward fewer transfusions and suggests a change in physician culture and behavior. We recommend other hospitals consider similar versions of this strategy appropriate for their circumstances since it benefits patients and reduces health care costs. Disclosures: No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document